RPE tears can occur after intravitreal injection of bevacizumab. The low incidence of this adverse event should not preclude anti-vascular endothelial growth factor therapy counseling for patients with neovascular AMD, but eyes with serous RPE detachments appear to be most vulnerable to this adverse event.

To evaluate the effects of WIN 55212-2, a cannabinoid receptor agonist, on intraocular pressure and aqueous humor dynamics in normal monkeys and monkeys with glaucoma.Methods: Intraocular pressure was measured prior to and up to 6 hours after the topical administration of WIN 55212-2 to 1 eye of 5 normal monkeys and to the glaucomatous eye of 8 monkeys with unilateral laser-induced glaucoma. Tonographic outflow facility and fluorophotometric flow rates of aqueous humor were measured in 6 normal monkeys before and after treatment.Results: In normal monkeys, a single dose of WIN 55212-2 reduced intraocular pressure for 4, 5, or 6 hours, with a maximum reduction of 1.4 ± 0.4 (mean ± SEM) mm Hg, 2.9±0.4 mm Hg, and 3.4 ± 0.6 mm Hg following the 0.07%, 0.2%, and 0.5% concentrations, respectively (P = .08). In 8 glaucomatous monkey eyes, the ocular hypotensive effect was maintained for 5 days with twice-daily administration of 0.5% WIN 55212-2. Outflow facility was unchanged (P = .34) and aqueous humor flow was decreased by 18% (P=.04) in the treated eyes compared with vehicle-treated contralateral control eyes in normal monkeys.Conclusions: WIN 55212-2, a cannabinoid agonist at the CB 1 receptor, reduces intraocular pressure in both normal and glaucomatous monkey eyes. A decrease of aqueous flow appears to account for the intraocular pressure reduction in normal monkey eyes.Clinical Relevance: Cannabinoid agonists at the CB 1 receptor, a new class of antiglaucoma agents that is different from currently used clinical drugs, may have clinical potential.

No abstract

Wavefront-guided LASIK was an effective, predictable, and safe procedure for consecutive hyperopia and compound hyperopic astigmatism after LASIK.